Furthermore, the co-incubation of cisplatin and anti-CD133-CAR NK92 cells on ovarian cancer cells resulted in increased cell death compared to cisplatin alone, implicating CD133-directed NK cell killing as a possible adjuvant agent for cisplatin-based regimens. Here, PROM1 is linked to ovarian cancer.